Catherine Loveland-Jones1, Heather Lin2, Yu Shen2, Isabelle Bedrosian2, Simona Shaitelman2, Henry Kuerer2, Wendy Woodward3, Naoto Ueno3, Vicente Valero3, Gildy Babiera4. 1. MD Anderson Cancer Center at Cooper, Camden, New Jersey. 2. University of Texas, MD Anderson Cancer Center, Houston, Texas. 3. University of Texas, MD Anderson Cancer Center, Houston, Texas; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas. 4. University of Texas, MD Anderson Cancer Center, Houston, Texas; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas. Electronic address: gvbabiera@mdanderson.org.
Abstract
PURPOSE: Although radiation therapy improves locoregional control and survival for inflammatory breast cancer (IBC), it is underused in this population. The purpose of this study was to identify variables associated with the underuse of postmastectomy radiation therapy (PMRT) for IBC. METHODS AND MATERIALS: Using the 1998 to 2011 National Cancer Data Base, we identified 8273 women who underwent mastectomy for nonmetastatic IBC. We used logistic regression modeling to determine the demographic, tumor, and treatment variables associated with the underuse of PMRT. RESULTS: Although the use of PMRT increased over time, a total of 30.3% of our cohort did not receive PMRT. On multivariate analysis, variables associated with the underuse of PMRT for IBC included the following (all P<.05): Medicare insurance (odds ratio [OR] = 0.70), annual income <$34,999 (<$30,000: OR=0.79; $30,000-$34,999: OR=0.82), cN2 and cN0 disease (cN2: OR=0.71; cN0: OR=0.63), failure to receive chemotherapy and hormone therapy (chemotherapy: OR=0.15; hormone therapy: OR=0.35), treatment at lower-volume centers (OR=0.83), and treatment in the South and West (South: OR=0.73; West: OR=0.80). Greater distance between patient's residence and radiation facility was also associated with the underuse of PMRT (P=.0001). CONCLUSIONS: Although the use of PMRT for IBC has increased over time, it continues to be underused. Disparities related to a variety of variables impact which IBC patients receive PMRT. A concerted effort must be made to address these disparities in order to optimize the outcomes for IBC. Published by Elsevier Inc.
PURPOSE: Although radiation therapy improves locoregional control and survival for inflammatory breast cancer (IBC), it is underused in this population. The purpose of this study was to identify variables associated with the underuse of postmastectomy radiation therapy (PMRT) for IBC. METHODS AND MATERIALS: Using the 1998 to 2011 National Cancer Data Base, we identified 8273 women who underwent mastectomy for nonmetastatic IBC. We used logistic regression modeling to determine the demographic, tumor, and treatment variables associated with the underuse of PMRT. RESULTS: Although the use of PMRT increased over time, a total of 30.3% of our cohort did not receive PMRT. On multivariate analysis, variables associated with the underuse of PMRT for IBC included the following (all P<.05): Medicare insurance (odds ratio [OR] = 0.70), annual income <$34,999 (<$30,000: OR=0.79; $30,000-$34,999: OR=0.82), cN2 and cN0 disease (cN2: OR=0.71; cN0: OR=0.63), failure to receive chemotherapy and hormone therapy (chemotherapy: OR=0.15; hormone therapy: OR=0.35), treatment at lower-volume centers (OR=0.83), and treatment in the South and West (South: OR=0.73; West: OR=0.80). Greater distance between patient's residence and radiation facility was also associated with the underuse of PMRT (P=.0001). CONCLUSIONS: Although the use of PMRT for IBC has increased over time, it continues to be underused. Disparities related to a variety of variables impact which IBC patients receive PMRT. A concerted effort must be made to address these disparities in order to optimize the outcomes for IBC. Published by Elsevier Inc.
Authors: Linda C Harlan; Amanda L Greene; Limin X Clegg; Margaret Mooney; Jennifer L Stevens; Martin L Brown Journal: J Clin Oncol Date: 2005-11-21 Impact factor: 44.544
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: Shervin M Shirvani; I-Wen Pan; Thomas A Buchholz; Ya-Chen Tina Shih; Karen E Hoffman; Sharon H Giordano; Benjamin D Smith Journal: Cancer Date: 2011-06-27 Impact factor: 6.860
Authors: Anthony E Dragun; Bin Huang; Saurabh Gupta; John B Crew; Thomas C Tucker Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-01 Impact factor: 7.038
Authors: Eleftherios P Mamounas; Stewart J Anderson; James J Dignam; Harry D Bear; Thomas B Julian; Charles E Geyer; Alphonse Taghian; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2012-10-01 Impact factor: 44.544
Authors: Gary V Walker; Sharon H Giordano; Melanie Williams; Jing Jiang; Jiangong Niu; Jill MacKinnon; Patricia Anderson; Brad Wohler; Amber H Sinclair; Francis P Boscoe; Maria J Schymura; Thomas A Buchholz; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2013-07-15 Impact factor: 7.038
Authors: Barbara L Fowble; John P Einck; Danny N Kim; Susan McCloskey; Jyoti Mayadev; Catheryn Yashar; Steven L Chen; E Shelley Hwang Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-01 Impact factor: 7.038
Authors: Tithi Biswas; Charulata Jindal; Timothy L Fitzgerald; Jimmy T Efird Journal: Int J Environ Res Public Health Date: 2019-01-04 Impact factor: 3.390